Sage Acquisition - Narrative (Details) $ / shares in Units, $ in Thousands		2 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2025 USD ($) right $ / shares	Sep. 30, 2025 USD ($) $ / shares	Sep. 30, 2025 USD ($) $ / shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) $ / shares	Sep. 30, 2024 USD ($)	Jun. 16, 2025 $ / shares	Dec. 31, 2024 USD ($) $ / shares
Business Combination [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.001	$ 0.001		$ 0.001			$ 0.001
Contingent consideration		$ 11,448	$ 11,448		$ 11,448			$ 47,340
Share-based compensation expense			30,745	$ 7,674	46,320	$ 20,123
Sage Therapeutics, Inc.
Business Combination [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Sage Therapeutics, Inc.
Business Combination [Line Items]
Business combination, price per share (in dollars per share) | $ / shares	$ 8.50
Aggregate consideration paid	$ 561,000
Contingents value rights | right	1
Contingent consideration, maximum	$ 234,000
Rights per share (in dollars per share) | $ / shares	$ 3.50						$ 3.50
Acquisition-related expenses			$ 8,600		10,000
Contingent consideration	$ 11,448
Contingent consideration, minimum	0
Business combination, consideration transferred, liabilities incurred	4,100
Share-based compensation expense	$ 22,900
Business combination, total revenue		20,100
Business combination, net loss		$ 65,400
Post-combination employee-related expenses					$ 38,000